Amycretin, Novo Nordisk’s new experimental oral drug for weight loss delivered early Phase I results showing an impressive 13.1% weight loss after 12 weeks
In comparison, Wegovy patients achieved ~6% weight loss while placebo patients lost ~1%
‘Amycretin is a GLP-1 and amylin receptor agonist that Novo is hoping will show additive benefits with a differentiated mode of action from its comparable GLP-1 drug semaglutide, marketed as Wegovy for weight loss and Ozempic for diabetes. The oral therapy is dosed once daily—which could prove to be a huge improvement over the weekly injections of Wegovy and competitor Zepbound, which is marketed by Eli Lilly.’
Once again Novo Nordisk shows it’s really got game when it comes to driving innovation and market share in Diabetes / Obesity care